What is the best medication for treating increased agitation associated with sundowning in patients with dementia?

Best Medicine for Sundowning-Related Agitation

Nonpharmacological interventions should be attempted first, but if medication is necessary for severe, dangerous, or significantly distressing sundowning agitation, start with a low-dose atypical antipsychotic (risperidone 0.25-0.5 mg) after discussing risks including increased mortality with the patient's decision-maker. 1

When to Use Medication

Medication should only be considered when 1:

• Symptoms are severe
• Behavior is dangerous (risk of harm to self or others)
• Patient experiences significant distress

Critical caveat: The APA guidelines emphasize that antipsychotics have "at best small" benefits in clinical trials and are "associated with clinically significant adverse effects, including mortality." 1 This means you must have a serious risk-benefit discussion before prescribing.

Stepwise Approach

Step 1: Rule Out and Address Reversible Causes

Before any medication 1:

• Assess for pain (often undertreated and a major agitation trigger)
• Check for infection (UTI, pneumonia)
• Review medications for delirium-inducing drugs
• Evaluate for constipation, urinary retention
• Assess environmental triggers specific to evening hours

Step 2: Trial Nonpharmacological Interventions First

Document that you've attempted person-centered approaches before prescribing 1:

• Structured evening routines
• Light therapy during the day
• Reducing stimulation in evening hours
• Redirecting activities

Step 3: Medication Selection (If Nonpharmacological Fails)

First-line pharmacological option:

• Risperidone starting at 0.25-0.5 mg at bedtime 2, 3, 4
  • Most commonly recommended atypical antipsychotic across European guidelines (18 countries) 4
  • Titrate slowly to minimum effective dose (usually 0.5-1 mg)
  • Monitor for extrapyramidal symptoms, though lower risk than typical antipsychotics

Alternative considerations:

• Quetiapine 12.5-25 mg at bedtime 5, 6, 4
  • Recent 2025 evidence shows lowest frequency of adverse events compared to other antipsychotics (OR 0.27) 5
  • May be preferred if patient has Parkinson's features or high fall risk

Avoid benzodiazepines:

• Midazolam poses excessive risk (5.25 times higher adverse events than haloperidol) 5
• Benzodiazepines worsen delirium and increase fall risk in elderly

Step 4: Adjunctive or Alternative Agents

For patients already on dementia medications:

• Ensure cholinesterase inhibitors (donepezil, rivastigmine) are optimized 7, 3
  • May specifically help sundowning patterns
  • One case report showed marked reduction in evening activity with donepezil 7

If insomnia is prominent component:

• Trazodone 25-50 mg at bedtime 6
  • Address sleep-wake cycle disruption
  • Lower risk profile than antipsychotics

Melatonin 3-9 mg at bedtime 8, 9:

• Older evidence (2002-2010) suggests improvement in sundowning
• Targets circadian rhythm disturbance directly
• Very low risk, reasonable to try before or alongside antipsychotics
• Effect size uncertain but safe option

Citalopram - NOT recommended based on newest evidence:

• 2025 trial of escitalopram (the "safer" enantiomer) showed no efficacy and caused QT prolongation 10
• Despite older recommendations for citalopram, the 2025 data suggests SSRIs are not effective for agitation 10

Monitoring and Reassessment

After starting antipsychotic 1:

• Use quantitative measure to track response (e.g., Cohen-Mansfield Agitation Inventory)
• If no response after 4 weeks at adequate dose → taper and discontinue
• If significant side effects occur → reassess risk-benefit, consider tapering
• If positive response → discuss tapering attempt after 3-6 months of stability

Critical Safety Warnings

Black box warning considerations:

• All antipsychotics increase mortality risk in elderly with dementia
• Increased risk of stroke/cerebrovascular events
• Must document informed consent discussion with surrogate decision-maker 1

Highest risk medication to avoid:

• Midazolam and other benzodiazepines have unacceptably high adverse event rates in this population 5

Summary Algorithm

1. Assess and treat pain, infection, medication effects
2. Trial nonpharmacological interventions for 1-2 weeks
3. If severe/dangerous → Risperidone 0.25-0.5 mg HS (or quetiapine 12.5-25 mg if fall risk/EPS concern)
4. Consider adding melatonin 6 mg HS for circadian component
5. Reassess at 4 weeks → continue only if clear benefit
6. Attempt taper after 3-6 months of stability